Knowledge Repository
-
BROWSE
-
ICDDR,B PUBLICATIONS
-
CONNECT
Antigen-specific memory B-cell responses in Bangladeshi adults after one or two dose oral killed cholera vaccination, and comparison with responses following natural cholera
Download
Adobe PDF
(986.97 kB)
Published
2011
Author(s)
Alam, Mohammad Murshid
Riyadh, M. Asrafuzzaman
Fatema, Kaniz
Rahman, Mohammad Arif
Akhtar, Nayeema
Ahmed, Tanvir
Chowdhury, Mohiul Islam
Chowdhury, Fahima
Calderwood, Stephen B.
Harris, Jason B.
Ryan, Edward T.
Qadri, Firdausi
Metadata
The mediators of protective immunity against cholera are currently unknown, but memory B-cell responses
may play a central role in facilitating long-term and anamnestic responses against Vibrio cholerae, the cause
of cholera. We compared memory B-cell responses in adults with natural cholera in Bangladesh (n 70) to
responses in Bangladeshi adults after one-dose (n 30) or two-dose (n 30) administration of an oral killed
cholera vaccine, WC-rBS (Dukoral; Crucell), assessing the responses at the acute stage of disease or prevaccination
and then on days 3, 30, 90, 180, 270, and 360. Individuals with natural cholera developed prominent
vibriocidal and plasma anti-cholera toxin B subunit (CtxB) and lipopolysaccharide (LPS) IgG and IgA
responses, but these responses returned to baseline by 1 year of follow-up. Vaccinees developed plasma
anti-CtxB and anti-LPS IgG and IgA responses that were generally comparable to those in individuals
recovering from natural disease, but vibriocidal responses were lower in vaccinees than in infected patients.
Individuals recovering from natural disease developed memory B-cell IgG and IgA anti-CtxB and anti-LPS
responses by day 30, and these responses were detectable through at least days 180 to 360. In contrast, we
detected no IgA or IgG memory B-cell responses to LPS in vaccinees; anti-CtxB IgA responses were only
detectable on day 30, and anti-CtxB IgG responses were detectable until days 90 to 180, compared to days 270
to 360 in patients. These findings may explain in part the relatively short-term protection afforded by oral
cholera vaccination compared to natural disease.
Citation
Clin Vaccine Immunol 2011 May;18(5):844-50